期刊文献+

慢性肾脏病患者铁缺乏及铁代谢 被引量:6

Iron deficiency and iron metabolism in chronic kidney disease patients
下载PDF
导出
摘要 慢性肾脏病患者常伴有不同程度的铁缺乏和铁代谢紊乱,铁调素、炎症、红细胞生成素、低氧诱导因子等参与上述过程。临床上将铁缺乏分为绝对性铁缺乏和功能性铁缺乏,铁调素、铁蛋白、转铁蛋白饱和度是评价和鉴别铁缺乏有效的指标。临床上合理选择和补充铁剂、降低铁调素水平、改善铁代谢紊乱对治疗慢性肾脏病铁缺乏非常重要。 Chronic kidney disease(CKD) patients are often accompanied by various degrees of iron deficiency and iron metabolism disorders;hepcidin, inflammation, erythropoietin and hypoxia-inducing factors are involved in the abnormalities. Iron deficiency can be classified into absolute iron deficiency and functional iron deficiency. Hepcidin, ferritin and transferrin saturation are useful markers to evaluate and diagnose iron deficiency. Clinically, rational use of iron supplements, reduction of hepcidin level, and improvement of iron metabolism are critical in the treatment of iron deficiency in CKD patients.
作者 陈吉林 林洪丽 CHEN Ji-lin;LIN Hong-li(Department of Nephrology,the First Affiliated Hospital of Dalian Medical University,Dalian 116011,China)
出处 《中国血液净化》 CSCD 2020年第6期368-371,共4页 Chinese Journal of Blood Purification
关键词 慢性肾脏病 铁代谢 铁缺乏 铁调素 Chronic kidney disease Iron metabolism Iron deficiency Hepcidin
  • 相关文献

参考文献1

二级参考文献14

  • 1Portoles J, Lopez-Gomez JM, Aljama P. Anemia management and treatment response in patients on hemodialysis: the MAR study[J]. J Nephrol, 2006,19:352- 360.
  • 2KDOOI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease[J]. Am J Kidney Dis, 2006,47:S11-145.
  • 3Brookhart MA, Schneeweiss S, Avorn J, et al. The effect of altitude on dosing and response to erythropoietin in ESRD [J]. J Am Soc Nephrol, 2008,19:1389- 1395.
  • 4Riedel MK, Morgenstern T. Iron replacement in hemodialysis patients with a normal serum ferritin level[J]. Dtseh Med Wochenschr, 2004,129:1849 1853.
  • 5Jacobs C, Frei D, Perkins AC. Results of the European Survey on Anaemia Management 2003 (ESAM 2003): current status of anaemia management in dialysis patients, factors affecting epoetin dosage and changes in anaemia management over the last 5 years[J]. Nephrol Dial Transplant, 2005,20 Suppl 3:iii3 -24.
  • 6Reis KA, Guz G, Ozdemir H, et al. Intravenous iron therapy as a possible risk factor for atherosclerosis in end-stage renal disease[J]. Int Heart J, 2005,46:255-264.
  • 7Lenga I, Lok C, Marticorena R, et al. Role of oral iron in the management of long term hemodialysis patients[J], Clin J Am Soe Nephrol, 2007,2:688-693.
  • 8Rozen Zvi B, Gafter Gvili A, Paul M, et al. Intravenous versus oral iron supplementation for the treatment of anemia in CKD: systematic review and meta anaIysls[J]. Am J Kidney Dis, 2008,52:897-906.
  • 9Sargent JA, Acchiardo SR. Iron requirements in hemodialysis [J]. Blood Purif. 2004,22:112-123.
  • 10Anirban G, Kohli HS, Jha V, et al. The comparative safety of various intravenous iron preparations in chronic kidney disease patients[J]. Ren Fail, 2008,30:629-638.

共引文献12

同被引文献51

引证文献6

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部